Publication details
RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION
| Authors | |
|---|---|
| Year of publication | 2009 |
| Type | Article in Periodical |
| Magazine / Source | BIOMEDICAL PAPERS-OLOMOUC |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | Diffuse large B-cell lymphoma; Rituximab; Stem cell transplantation |
| Description | The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation in 69 patients with poor-risk, diffuse large B cell lymphoma. A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x10(6)/kg in the nonR group and 7.81x10(6)/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x10(4)/kg) compared to the R group (76.6x10(4)/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x10(4)/kg) than the R patients (31.3x10(4)/kg; p = 0.001). Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival (94,7 % vs 83,5 %; p = 0.179). |